Biosimilars and Biologics in Cancer Therapy: An Era in Therapeutic Strategies addresses challenges and opportunities in biosimilars and biologics, integrating the latest evidence, regulatory landscapes, economic implications, and strategies to enhance cancer management. The book aims to create an all-inclusive educational resource, bridge the gap between research and clinical practice, and inspire future research in oncology. It provides a comprehensive examination of cancer therapeutics, starting with an introduction to biologics and biosimilars, their historical development, and foundational principles. Sections explain mechanisms of action, drug development processes, regulatory landscapes, and clinical applications through case studies.
Emerging therapeutic strategies, including combination therapies and personalized medicine, are also covered. This book benefits researchers, oncologists, pharmacologists, pathologists, and other healthcare professionals by offering up-to-date insights into the clinical aspects of biological medications and their biosimilars. Contributions from global experts ensure readers gain the latest advancements and practical guidance on integrating these therapies into clinical practice and research.
1. Chapter 1 Introduction to biosimilars and biologics - p. 1 2. Chapter 2 Biosimilars and biologics in breast cancer - p. 27 3. Chapter 3 Biosimilars and biologics in gastric and colorectal carcinoma - p. 53 4. Chapter 4 Biosimilars and biologics in cervical cancer - p. 83 5. Chapter 5 Biosimilars and biologics in lung cancer - p. 115 6. Chapter 6 Biosimilars and biologics in hepatocellular carcinoma - p. 137 7. Chapter 7 Biosimilars and biologics in the treatment of brain tumor - p. 161 8. Chapter 8 Biosimilars and biologics in pancreatic cancer - p. 183 9. Chapter 9 Biosimilars and biologics in prostate cancer - p. 207 10. Chapter 10 Biosimilars and biologics in ovarian cancer - p. 237 11. Chapter 11 Biosimilars and biologics in bone cancer - p. 261 12. Chapter 12 Biologics and biosimilars in endometrial cancer - p. 287 13. Chapter 13 Biosimilars and biologics in urothelial carcinoma - p. 313 14. Chapter 14 Biosimilars and biologics in melanoma - p. 361 15. Chapter 15 Biologics and biosimilars from the bench to the bedside in oncology - p. 383 16. Chapter 16 Recent evidence of biologics and biosimilars and its perspectives on clinical advances and emerging approaches in cancer - p. 427 17. Chapter 17 Marching of biologics and biosimilars in artificial intelligence and machine learning as tools to detect various cancers - p. 463 18. Index - p. 501
Biosimilars and Biologics in Cancer Therapy: An Era in Therapeutic Strategies addresses challenges and opportunities in biosimilars and biologics, integrating the latest evidence, regulatory landscapes, economic implications, and strategies to enhance cancer management. The book aims to create an all-inclusive educational resource, bridge the gap between research and clinical practice, and inspire future research in oncology. It provides a comprehensive examination of cancer therapeutics, starting with an introduction to biologics and biosimilars, their historical development, and foundational principles. Sections explain mechanisms of action, drug development processes, regulatory landscapes, and clinical applications through case studies.
Emerging therapeutic strategies, including combination therapies and personalized medicine, are also covered. This book benefits researchers, oncologists, pharmacologists, pathologists, and other healthcare professionals by offering up-to-date insights into the clinical aspects of biological medications and their biosimilars. Contributions from global experts ensure readers gain the latest advancements and practical guidance on integrating these therapies into clinical practice and research.
1. Chapter 1 Introduction to biosimilars and biologics - p. 1 2. Chapter 2 Biosimilars and biologics in breast cancer - p. 27 3. Chapter 3 Biosimilars and biologics in gastric and colorectal carcinoma - p. 53 4. Chapter 4 Biosimilars and biologics in cervical cancer - p. 83 5. Chapter 5 Biosimilars and biologics in lung cancer - p. 115 6. Chapter 6 Biosimilars and biologics in hepatocellular carcinoma - p. 137 7. Chapter 7 Biosimilars and biologics in the treatment of brain tumor - p. 161 8. Chapter 8 Biosimilars and biologics in pancreatic cancer - p. 183 9. Chapter 9 Biosimilars and biologics in prostate cancer - p. 207 10. Chapter 10 Biosimilars and biologics in ovarian cancer - p. 237 11. Chapter 11 Biosimilars and biologics in bone cancer - p. 261 12. Chapter 12 Biologics and biosimilars in endometrial cancer - p. 287 13. Chapter 13 Biosimilars and biologics in urothelial carcinoma - p. 313 14. Chapter 14 Biosimilars and biologics in melanoma - p. 361 15. Chapter 15 Biologics and biosimilars from the bench to the bedside in oncology - p. 383 16. Chapter 16 Recent evidence of biologics and biosimilars and its perspectives on clinical advances and emerging approaches in cancer - p. 427 17. Chapter 17 Marching of biologics and biosimilars in artificial intelligence and machine learning as tools to detect various cancers - p. 463 18. Index - p. 501
